v3.10.0.1
Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($)
3 Months Ended 9 Months Ended
Sep. 30, 2018
Sep. 30, 2017
Sep. 30, 2018
Sep. 30, 2017
Revenue:        
Grant and licensing revenue $ 1,840,009 $ 470,823 $ 3,735,713 $ 906,313
Operating expenses:        
Research and development 4,403,759 1,823,922 10,756,485 5,788,755
General and administrative 1,585,600 1,188,476 4,727,105 4,298,072
Change in fair value of contingent consideration 114,838 665,936
Total operating expenses 6,104,197 3,012,398 16,149,526 10,086,827
Loss from operations (4,264,188) (2,541,575) (12,413,813) (9,180,514)
Interest income 83,509 5,629 131,306 17,316
Other income, net 31,704 31,768 153,500 109,211
Total non-operating income, net 115,213 37,397 284,806 126,527
Net loss before income tax benefit (4,148,975) (2,504,178) (12,129,007) (9,053,987)
Income tax benefit 225,389 665,080
Net loss (3,923,586) (2,504,178) (11,463,927) (9,053,987)
Net loss - non-controlling interest (265,024) (203,371) (668,219) (344,328)
Net loss attributable to Heat Biologics, Inc. $ (3,658,562) $ (2,300,807) $ (10,795,708) $ (8,709,659)
Net loss per share attributable to Heat Biologics, Inc.-basic and diluted $ (0.16) $ (0.64) $ (0.75) $ (2.66)
Weighted-average number of common shares used in net loss per share attributable to common stockholders-basic and diluted 23,143,952 3,578,661 14,359,429 3,269,536
Other comprehensive loss:        
Net loss $ (3,923,586) $ (2,504,178) $ (11,463,927) $ (9,053,987)
Unrealized gain /(loss) on foreign currency translation 39,377 (24,707) 110,648 (100,742)
Total other comprehensive loss (3,884,209) (2,528,885) (11,353,279) (9,154,729)
Comprehensive loss attributable to non-controlling interest (265,024) (203,371) (668,219) (344,328)
Comprehensive loss $ (3,619,185) $ (2,325,514) $ (10,685,060) $ (8,810,401)

Source